Drug & intervention
finerenone
RxCUI 2562811
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
26 shownEfficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary AldosteronismNCT07688928 · 2026-04-15
RECRUITINGUse of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney DiseaseNCT06727409 · 2024-12-12
RECRUITINGA Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsNCT06033950 · 2024-08-20
RECRUITINGA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)NCT06024746 · 2024-07-09
RECRUITINGMultifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · 2024-07-01
RECRUITINGA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsNCT06008197 · 2024-01-17
RECRUITINGEvaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney DiseaseNCT06838416 · 2023-11-17
RECRUITINGPrecision T1D Platform - New Therapies for Cardio-Renal ComplicationsNCT07594145 · 2026-11-01
NOT_YET_RECRUITINGA Study to Learn More About How Well Finerenone Works in Real-World in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)NCT07841015 · 2026-09-30
NOT_YET_RECRUITINGFinerenone and Cardiac Remodeling in HFpEFNCT07830940 · 2026-09-20
NOT_YET_RECRUITINGStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNCT07849348 · 2026-09-01
NOT_YET_RECRUITINGQUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyNCT07775846 · 2026-09-01
NOT_YET_RECRUITINGFinerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor AnalysisNCT07717697 · 2026-07-30
NOT_YET_RECRUITINGFinerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart FailureNCT07575672 · 2026-07-01
NOT_YET_RECRUITINGEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · 2026-05-01
NOT_YET_RECRUITINGRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)NCT07547878 · 2026-04-30
NOT_YET_RECRUITINGSpironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety StudyNCT07523867 · 2026-04-01
NOT_YET_RECRUITINGInvestigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart FailureNCT07442448 · 2026-04-01
ENROLLING_BY_INVITATIONFinerenone Plus SGLT2 Inhibitors in Heart FailureNCT07351864 · 2026-01-18
NOT_YET_RECRUITINGFinerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart FailureNCT07326631 · 2026-01-01
NOT_YET_RECRUITINGFinerenone and Cardiac RemodelingNCT07270367 · 2025-12-01
NOT_YET_RECRUITINGTreatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialNCT06094920 · 2024-07-29
COMPLETEDThe Clinical Efficacy and Safety of Finerenone in the Treatment of Primary AldosteronismNCT06381323 · 2024-03-01
COMPLETEDA Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 DiabetesNCT05901831 · 2024-02-26
COMPLETEDEffects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)NCT05887817 · 2023-09-07
UNKNOWNComparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary AldosteronismNCT05814770 · 2023-05-01
UNKNOWNConditions being studied
Heart Failure9Chronic Kidney Disease3Primary Aldosteronism3Type 2 Diabetes3Chronic Kidney Diseases2Diabetic Kidney Disease2Finerenone2Type 1 Diabetes2Type 2 Diabetes Mellitus2Acute Heart Failure1Albuminuria1Cardio-renal Vascular Function and Failure1Cardiovascular Diseases1Chronic Kidney Disease (CKD) Stages G2 to G3b1Chronic Kidney Disease Due to Type 2 Diabetes Mellitus1Chronic Kidney Disease stage31Chronic Kidney Disease stage41CKD1CKD - Chronic Kidney Disease1CKD Stage 31
Research locations
TorontoOntario, Canada5EdmontonAlberta, Canada4GlasgowUnited Kingdom4GreenvilleNorth Carolina, United States4MiamiFlorida, United States4NorfolkVirginia, United States4AtlantaGeorgia, United States3AuroraColorado, United States3AustinTexas, United States3BarcelonaSpain3Baton RougeLouisiana, United States3BradentonFlorida, United States3
Leading sponsors
Colorado Prevention Center3Bayer2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2Assiut University1Bangladesh Medical University1Baylor Research Institute1Cathay General Hospital1Chinese University of Hong Kong1College of Physicians and Surgeons Pakistan1First Affiliated Hospital of Chongqing Medical University1First Affiliated Hospital of Wannan Medical College1Hospital de Messejana Dr. Carlos Alberto Studart Gomes1Huijie Zhang1Mansoura University1Oregon Health and Science University1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.